• Torna ai siti globali
  • +44 (0)20 7454 5110
  • GDPR
  • Giornalisti
  • Richiedi maggiori informazioni
PR Newswire: news distribution, targeting and monitoring
  • Notizie
  • Prodotti
  • Contatto
  • PR Newswire: news distribution, targeting and monitoring
  • Richiedi maggiori informazioni
    • Telefono

    • +44 (0)20 7454 5110 da 8 AM - 5 PM GMT

    • Contattaci
    • Contattaci

      +44 (0)20 7454 5110
      da 8 AM - 5 PM GMT

  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR
  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR
  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR
  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR

Diluent or Immuno-Reagent solutions for your diagnostic testing kits (Covid, Flu, etc.)
  • France - Français
  • USA - English
  • Deutschland - Deutsch
  • Italia - Italiano
  • España - español

Unither_Pharmaceuticals_Logo

Notizia fornita da

Unither Pharmaceuticals

23 mar, 2021, 07:00 GMT

Condividi articolo

Share this article


PARIS, March 23, 2021 /PRNewswire/ -- Unither Pharmaceuticals, the Blow-Fill-Seal (BFS) worldwide leader, provides diagnostic companies with capacity solutions and innovative technologies for their testing kits (Covid, Flu, etc.).

With more than 10 million unit-doses manufactured each month for Covid testing kits, the French CDMO answers to current challenges based on its sterile unit doses development and manufacturing expertise.

Diluent or Immuno-Reagent solutions for your diagnostic testing kits (Covid, Flu, etc.)

The use of Blow-Fill-Seal technology, enables RNase-free single doses, that can also be sterile if necessary.

Through its 5 BFS plants on three continents (in France, the United States and China) and a R&D development center, Unither is able to manage the full development of a diluent or reagent from formulation to production.

About Unither Pharmaceuticals

Founded in Amiens, France, in 1993, Unither Pharmaceuticals has become a worldwide leader in drug manufacturing for generic pharmaceutical companies including but not limited to, eye drops and respiratory unit doses, saline solutions, and stick-packs.  

Unither Pharmaceuticals has 7 manufacturing sites and 1 R&D center located in France, the United States, China and Brazil. These sites generated a revenue of €330 million in 2020 with a headcount exceeding 1.600 employees.

Website : www.unither-pharma.com

Blow-Fill-Seal : https://www.unither-pharma.com/technologies-innovations/blow-fill-seal-bfs/?lang=en

Article : https://www.unither-pharma.com/news/diluent-or-immuno-reagent-solutions-for-your-diagnostic-testing-kits-covid-flu-etc/?lang=en

Contact: [email protected]

Photo: https://mma.prnewswire.com/media/1471718/Diluent_or_Immuno_Reagent_solutions.jpg  
Logo: https://mma.prnewswire.com/media/1471719/Unither_Pharmaceuticals_Logo.jpg

SOURCE Unither Pharmaceuticals

Modal title

Sempre da questa fonte

Soluzioni diluenti o immunoreagenti per i vostri kit di test...

Soluzioni diluenti o immunoreagenti per i vostri kit di test...

Esplora

Altri comunicati stampa di argomenti simili

  • Biotechnology
  • Health Care & Hospitals
  • Medical Equipment
  • Medical Pharmaceuticals
  • New Products & Services

    Contatta PR Newswire

  • +44 (0)20 7454 5110
    da 8 AM - 5 PM GMT

    Siti globali

  • Asia
  • Brasile
  • Canada
  • Ceco
  • Danimarca
  • Finlandia
  • Francia
  • Germania

     

  • India
  • Israele
  • Italia
  • Messico
  • Medio Oriente
  • Olanda
  • Norvegia
  • Polonia

     

  • Portogallo
  • Russia
  • Slovacchia
  • Spagna
  • Svezia
  • Regno Unito
  • Stati Uniti

Siti globali
  • Asia
  • Brasile
  • Canada
  • Ceco
  • Danimarca
  • Finlandia
  • Francia
  • Germania
  • India
  • Israele
  • Italia
  • Messico
  • Medio Oriente
  • Olanda
  • Norvegia
  • Polonia
  • Portogallo
  • Russia
  • Slovacchia
  • Spagna
  • Svezia
  • Regno Uniti
  • Stati Uniti
+44 (0)20 7454 5110
da 8 AM - 5 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2021 Cision US Inc.